- Home
- Publications
- Publication Search
- Publication Details
Title
Management of oral anticoagulation in the surgical patient
Authors
Keywords
-
Journal
ANZ JOURNAL OF SURGERY
Volume 85, Issue 9, Pages 620-625
Publisher
Wiley
Online
2015-04-20
DOI
10.1111/ans.13130
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management
- (2014) H. Tran et al. INTERNAL MEDICINE JOURNAL
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
- (2013) Hein Heidbuchel et al. EUROPACE
- Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
- (2013) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
- (2013) Todd H. Baron et al. NEW ENGLAND JOURNAL OF MEDICINE
- Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
- (2012) Jeff S. Healey et al. CIRCULATION
- Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
- (2012) M. D. LAMBOURNE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Determination of Rivaroxaban in Human Plasma Samples
- (2012) Job Harenberg et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Reversal of drug-induced anticoagulation: old solutions and new problems
- (2012) Walter “Sunny” Dzik TRANSFUSION
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
- (2011) K.-H. LIESENFELD et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
- (2011) Amitava Banerjee et al. THROMBOSIS AND HAEMOSTASIS
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
- (2010) Joachim Stangier et al. CLINICAL PHARMACOKINETICS
- Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism
- (2010) Celina Yong et al. Current Vascular Pharmacology
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations
- (2010) Edelgard Lindhoff-Last et al. THERAPEUTIC DRUG MONITORING
- The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?
- (2010) John W. Eikelboom et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- (2010) Joachim Stangier et al. THROMBOSIS AND HAEMOSTASIS
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
- (2009) Gregory Y.H. Lip et al. CHEST
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
- (2009) Joachim Stangier et al. CLINICAL PHARMACOKINETICS
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
- (2008) N. Raghavan et al. DRUG METABOLISM AND DISPOSITION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started